• HOME
  • Pipeline
  • Clinical Focus
  • Technology
  • Team
  • News
  • About
  • HOME
  • Pipeline
  • Clinical Focus
  • Technology
  • Team
  • News
  • About
  • canstockphoto6244971

    Febrile neutropenia is a common,
    life-threatening
    complication of chemotherapy

  • canstockphoto62820667

    Gut barrier Injury and Neutrophil
    depletion puts patients at risk for
    bacteremia and sepsis

  • canstockphoto7427952

    AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
    BACTERAEMIA BY STRENGTHENING
    INNATE GUT BARRIER DEFENSES

  • N1WT6iuIb

    eliminating the need for prophylactiC antibiotics

  • V1fz3suL-

    reducing risk of serious adverse events,
    antimicrobial resistance and
    microbiome dysbiosis

MORGUNBLAÐIÐ, 20/10 2017

November 15, 2017
Article in Icelandic - general introduction to Akthelia and its compounds. 
Lesa meira

A CLINICAL TRIAL SHOWS THAT ONE OF AKTHELIA’S ACTIVES SPEEDS RECOVERY OF TUBERCULOSIS.

June 22, 2016
A clinical trial performed by a consortium involving Akthelia’s founders has been completed. The trial involved 288 participants and tested one of Akthelia’s actives in combination with traditional antibiotics. The results show that Akthelia’s APIs improved clinical score and other clinical markers of Tuberculosis over using the traditional antibiotics alone. The results have been published in PLOS One (http://www.ncbi.nlm.nih.gov/pubmed/26394045).
Lesa meira

STEFAN JÖKULL SVEINSSON JOINS AKTHELIA’S BOARD

June 22, 2016

Akthelia is very proud to announce that Dr. Stefán Jökull Sveinsson has joined Akthelia’s board of directors. Dr. Sveinsson was Executive Vice President-Research & Development at Actavis for over 15 years where he directed drug development. Prior to that, he directed drug development at Delta and was a professor in Pharmacology at the University of Iceland. After leaving Actavis he has worked as an independent advisor in the pharmaceutical industry.

Lesa meira

AKTHELIA APPLIES FOR PATENT FOR A NEW CLASS OF CHEMICALS

June 1, 2016

Akthelia has applied for a patent for a novel class of pharmaceutically active ingredients (APIs) that induce the expression of antibacterial peptides. These APIs are small molecules that activate production of the antibacterial peptides in cell and animal models. Efficacy has been shown against Shigella and Vibrio cholera infections in rabbits.

Lesa meira

JÓN INGI BENEDIKTSSON JOINS AKTHELIA AS GENERAL MANAGER

June 22, 2016

Jón Ingi Benediktsson has joined Akthelia as General Manager. Jón Ingi has extensive experience in biotech investments. He was the CEO of Líftæknisjóðurinn (MP Bio) from November 2000 – April 2005, then he served as Director for the Akureyri University Research and Innovation Center. From January 2008 he was member of SEED Capital, the largest early stage venture fund in Denmark, life science investment team as Investment Manager and later on as Investment Director, responsible for their overall early stage life science investments. Akthelia is looking forward to having him on board.

Lesa meira

MEMBERS OF AKTHELIA MANAGEMENT PLAY MAJOR ROLES AT ANTIBACTERIAL CONFERENCE.

Antibacterial Conference.

October 10, 2009

Birgitta Agerberth, Director of Medical Microbial Pathogenesis of Akthelia Pharmaceuticals was one of two vice-chairs of the conference and also acted as a Discussion Leader during the session on „Understanding biology through the AMPs“. Guðmundur Hrafn Guðmundsson, Chairman of Akthelia‘s board of directors was a discussion leader during the session on „Regulation of AMP expression“ and presented his work in a poster. The participation of Drs Agerberth and Guðmundsson in the conference further establishes their leading role in the field of antibacterial peptides.

Lesa meira
  • Fyrri
    • 1
    • 2
  • Næsta

AKTHELIA

  • Grandagarði 16, 101 Reykjavik
  • akthelia@akthelia.is
  • 610502-6440
  • Twitter
© 2023 AKTHELIA